Neuroscience Video Recap—February 4, 2026

Welcome to the latest edition of Neuroscience Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

Neurocrine Biosciences has initiated a Phase 2 clinical trial to evaluate NBI-1065890 for the treatment of tardive dyskinesia, a neurological disorder commonly caused by long-term antipsychotic medication. The trial will assess the efficacy and safety of NBI-1065890, a next-generation VMAT2 inhibitor. If successful, this treatment could provide new hope for patients suffering from tardive dyskinesia, building on the success of Neurocrine’s previous VMAT2 inhibitor, valbenazine.

BioNxt Solutions has reported a 40% higher delivery of cladribine in a preclinical study involving multiple sclerosis. Their sublingual formulation, delivered as an oral dissolvable film, showed significantly improved systemic drug exposure compared to the conventional oral tablets. This enhanced delivery method could potentially lead to improved treatment outcomes and better tolerability for MS patients, offering them more flexibility in dosing.

Plus Therapeutics has provided an update on its clinical programs for REYOBIQ™ and CNSide®, both of which focus on treating central nervous system cancers. The company plans to optimize the dosing regimen for REYOBIQ™ and expand the availability of CNSide® to cover 150 million lives. These efforts could lead to increased access to critical diagnostic support for CNS cancers, significantly impacting patient care.

Sanofi has announced that its treatment, Venglustat, has met all primary endpoints in a Phase 3 trial for Type 3 Gaucher disease. The results show that Venglustat outperformed enzyme replacement therapy in improving the neurological symptoms associated with this rare disease. If approved, Venglustat could become the first treatment to address the neurological aspects of Type 3 Gaucher disease, marking a significant breakthrough in the treatment of this rare condition.

Otsuka has received FDA acceptance for the New Drug Application (NDA) for Centanafadine, a novel treatment for Attention Deficit Hyperactivity Disorder (ADHD). The FDA has set a Prescription Drug User Fee Act (PDUFA) date for July 24, 2026. If approved, Centanafadine will offer a new, first-in-class treatment option for ADHD, providing more therapeutic choices for patients suffering from this prevalent disorder.

AbbVie has launched Love in Mind™, a new initiative aimed at addressing the emotional impact of migraines on romantic relationships. A new survey highlights how migraines can disrupt intimacy and emotional well-being in relationships. By raising awareness of this issue, AbbVie hopes to foster open conversations and encourage more comprehensive care for patients suffering from migraines.

Lundbeck has presented new real-world data from the INFUSE study, which demonstrates the benefits of Vyepti® (eptinezumab) for chronic migraine patients. The study found that 75.7% of participants reported a significant improvement in migraine symptoms after two infusions of Vyepti®. This data suggests that Vyepti® could become an important treatment option for chronic migraine sufferers, especially those who have not responded well to other therapies.

Teva and Novartis have partnered to relaunch Mayzent® for patients with secondary progressive multiple sclerosis in Canada. Under this partnership, Teva will handle the commercialization of Mayzent® in Canada, expanding its availability to MS patients. This collaboration is set to improve access to this crucial treatment for secondary progressive MS patients, a group that has limited therapeutic options.

Stay ahead in neuroscience research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!